Cochlear implant with multi-layer electrode
A cochlear hearing aid system for providing electrical stimulation to auditory nerve fibers of a cochlea of a recipient of the cochlear hearing aid system is disclosed. The cochlear hearing aid system comprises a microphone configured to receive an acoustical signal and provide an audio signal based on the acoustical signal; a signal processor unit configured to receive the audio signal and process the audio signal; an electrode lead including a plurality of electrodes configured to stimulate the auditory nerve fibers based on the processed audio signal, wherein the electrode lead comprises: an electrode carrier maintaining the electrode contacts and wires, wherein the electrode carrier is made of silicone and is loaded by dexamethasone; a first layer (or sub-layers) of gelatin which is coated and chemically cross-linked selectively on a silicone outer surface of the electrode lead, wherein dexamethasone sodium phosphate is embedded in the first layer (or sub-layers); and a second layer of gelatin which is coated and physically cross-linked onto the first layer.
1 . An electrode lead, comprising:
an electrode carrier maintaining a plurality of electrode contacts and wires, wherein the electrode carrier is made of silicone and is loaded by dexamethasone;
a first layer of gelatin which is coated and chemically cross-linked selectively on a silicone outer surface of the electrode carrier, wherein dexamethasone sodium phosphate is embedded in the first layer; and
a second layer of gelatin which is coated and physically cross-linked onto the first layer.
2 . The electrode lead of claim 1 , wherein the first layer comprises a plurality of layers of gelatin that are coated and cross-linked in order to form the first layer.
3 . The electrode lead of claim 1 , wherein the first layer has a thickness of between 200 nm and 5 μm and/or is composed of a single layer or multiple layers.
4 . The electrode lead of claim 1 , wherein at least one of the first layer or the second layer includes a release drug solution.
5 . The electrode lead of claim 4 , wherein the release drug solution includes Dexamethasone Sodium Phosphate having a concentration of between 0.1 mg/mL and 100 mg/mL (saturated solution).
6 . The electrode lead of claim 5 , wherein a released Dexamethasone Sodium Phosphate concentration is between 0.1 and 175 μg in 70 μL of artificial perilymph.
7 . The electrode lead of claim 4 , wherein the release drug solution is configured to release a drug in a chosen duration of between 10 minutes and 1 day, depending on coating characteristics, in particular concentration, thickness and cross-linking.
8 . The electrode lead of claim 1 , wherein the first layer includes both a gelatin substance and a coupling agent.
9 . The electrode lead of claim 8 , wherein the gelatin substance of the first layer is coupled to stem cells targeting hair cells or neurons.
10 . The electrode lead of claim 1 , wherein a gelatin substance of the first layer is coupled to a Nerve Growth Factor (NGF).
11 . An electrode lead, comprising:
an electrode carrier comprising a plurality of electrode contacts and wires, wherein the electrode carrier is loaded by dexamethasone;
a first layer of gelatin chemically cross-linked to a surface of the electrode carrier, wherein dexamethasone sodium phosphate is embedded in the first layer of gelatin; and
a second layer of gelatin physically cross-linked to the first layer of gelatin.
12 . The electrode lead of claim 11 , wherein the gelatin of at least one of the first layer of gelatin or the second layer of gelatin comprises B-type gelatin.
13 . The electrode lead of claim 11 , wherein the first layer of gelatin comprises a thickness of approximately 2.5 μm.